Developer docs
API playgroundTry for free, no card

Search company profiles

Repare Therapeutics

Full company profile

uuid0002mmy

Namestring
Repare Therapeutics
Legal namestring
Repare Therapeutics Inc.
Websiteurl
reparerx.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Repare Therapeutics was a Canadian clinical-stage precision oncology company founded in 2016 and headquartered in Montreal with research operations in Cambridge, UK. The company applied its proprietary SNÅP synthetic lethality platform to identify DNA damage response (DDR) vulnerabilities in cancer cells and develop targeted therapies for genomically defined patient populations. Its clinical pipeline included camonsertib (ATR inhibitor for ATM-deficient tumors, developed under a CRADA with the U.S. National Cancer Institute), RP-3467 (Polθ ATPase inhibitor evaluated in the POLAR Phase 1 trial), RP-1664 (PLK4 inhibitor in the LIONS Phase 1 trial for TRIM37-high solid tumors), and lunresertib (PKMYT1 inhibitor).

The company operated an asset-centric, partnership-driven business model with no commercial product revenue. It generated income by advancing clinical assets through early-stage development and then out-licensing or selling them to larger pharmaceutical partners — notably Gilead Sciences (RP-3467, up to $30 million), Debiopharm (lunresertib worldwide license), and DCx Biotherapeutics (discovery platforms plus retained talent). Following a 25% workforce reduction in September 2024 and a further 75% reduction in February 2025, Repare divested most of its remaining assets and was acquired by XenoTherapeutics, Inc. in January 2026 for approximately $78.2 million plus contingent value rights, resulting in delisting from Nasdaq.

Short descriptiontext

Repare Therapeutics was a Canadian clinical-stage precision oncology company that used its proprietary SNÅP synthetic lethality platform to develop DDR inhibitors targeting genetically defined cancer populations, monetizing its pipeline through licensing deals and acquisition rather than commercial product sales.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology drugs, synthetic lethality platform, DNA damage response inhibitors, targeted cancer therapy, clinical-stage biotechnology
Industry2 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Precision Oncology Drug Development
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Asset Licensing and Acquisition
TypeLicensing Royalties
Description

Repare generated revenue through licensing agreements and asset sales to pharmaceutical partners. The company sold RP-3467 to Gilead Sciences for up to $30 million ($25M upfront + $5M milestone), licensed lunresertib to Debiopharm, and out-licensed discovery platforms to DCx Biotherapeutics.

fiercebiotech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Repare Therapeutics developed clinical-stage precision oncology drug candidates using its proprietary SNIPx synthetic lethality platform, which identifies synthetic lethal gene pairs to target DNA damage response vulnerabilities in genetically defined cancer patient populations. The company's pipeline included camonsertib (ATR inhibitor for ATM-deficient tumors), RP-3467 (Polθ ATPase inhibitor), RP-1664 (PLK4 inhibitor for TRIM37-high solid tumors), and lunresertib (PKMYT1 inhibitor). Value was realized through out-licensing clinical assets and discovery platforms to large pharmaceutical partners rather than direct commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 37.5% response rate in Phase 1 MYTHIC trial for lunresertib/camonsertib combination in advanced ovarian cancer
+1 more record
Product overview1 text field

Repare Therapeutics was a clinical-stage precision oncology company developing targeted cancer therapies using its proprietary SNÅP synthetic lethality platform. The company's pipeline included multiple clinical-stage drug candidates: camonsertib (ATR inhibitor for ATM-deficient tumors), RP-1664 (PLK4 inhibitor in Phase 1 LIONS trial), and lunresertib (PKMYT1 inhibitor licensed to Debiopharm). Prior to its acquisition by XenoTherapeutics in January 2026, the company sold RP-3467 (Polθ ATPase inhibitor) to Gilead Sciences for up to $30 million and out-licensed its discovery platforms to DCx Biotherapeutics. The company's approach focused on developing therapies that exploit genomic instability in cancer cells while sparing normal cells.

Product and service5 records
1Camonsertib (RP-3500)
CategoryClinical-stage oncology drug candidate (ATR inhibitor)
Description

An ATR inhibitor designed for the treatment of ATM-deficient tumors through a synthetic lethality mechanism, inhibiting ATR kinase in tumors that lack ATM function. Developed for genetically defined patient populations with DNA repair deficiencies.

2RP-3467
CategoryClinical-stage oncology drug candidate (Polθ ATPase inhibitor)
Description

A polymerase theta (Polθ) ATPase inhibitor evaluated in the POLAR Phase 1 clinical trial for safety and preliminary activity alone or in combination with olaparib in patients with various advanced cancers. Acquired by Gilead Sciences in December 2025 for up to $30 million.

3RP-1664
CategoryClinical-stage oncology drug candidate (PLK4 inhibitor)
Description

A PLK4 (Polo-like kinase 4) inhibitor evaluated in the Phase 1 LIONS clinical trial for solid tumors with TRIM37-high expression, representing a synthetic lethality approach to tumors with specific genomic alterations.

4Lunresertib (RP-6306)
CategoryClinical-stage oncology drug candidate (PKMYT1 inhibitor)
Description

A PKMYT1 inhibitor previously part of Repare's clinical pipeline for gynecologic cancers in combination with camonsertib. Exclusively licensed worldwide to Debiopharm in July 2025.

5SNIPx Synthetic Lethality Discovery Platform
CategoryDrug discovery platform (out-licensed)
Description

Repare's proprietary drug discovery platform for identifying synthetic lethality targets in DNA damage response pathways, enabling the development of precision cancer therapies for genetically defined patient populations. Sold as a standalone offering through out-licensing to DCx Biotherapeutics.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-28
Description

XenoTherapeutics, Inc., a Massachusetts-based 501(c)(3) nonprofit biotechnology research foundation focused on xenotransplantation, completed acquisition of Repare Therapeutics through a statutory plan of arrangement. Shareholders received cash payments and contingent value rights, resulting in delisting from Nasdaq and cessation of reporting obligations. Deal valued at approximately $78.2 million plus CVRs.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-24
Description

Gilead Sciences entered into a definitive asset purchase agreement to acquire Repare's Polθ ATPase inhibitor RP-3467 for up to $30 million, including $25 million upfront payment and $5 million upon technology transfer completion. The deal marked Repare's third and most significant portfolio transaction in 2025, with the upfront payment increasing shareholder payout in the pending XenoTherapeutics acquisition.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-08-01
Description

Repare Therapeutics entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, continuing the companies' prior collaboration. This partnership followed Repare's portfolio reprioritization and cost reduction initiatives, allowing the company to focus on core clinical assets while enabling lunresertib's continued development.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-05-04
Description

Repare Therapeutics announced out-licensing of its discovery platforms to DCx Biotherapeutics, a newly launched company. The transaction included retention of talent and infrastructure from Repare to accelerate development of multi-modal antibody drug conjugates.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-15
Description

Repare Therapeutics announced a CRADA (Cooperative Research and Development Agreement) with the US National Cancer Institute to advance development of camonsertib, an ATR inhibitor for ATM-deficient tumors. The partnership supports ongoing clinical development and provides access to NCI research capabilities and patient populations.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct synthetic lethality competitor with a precision oncology pipeline targeting DNA damage response and other genetically defined vulnerabilities, using functional genomics screens comparable to Repare's SNIP platform.

TypeDirect peer
Description

Precision oncology biotech developing synthetic lethality and DNA damage response (DDR) therapies, including MAT2A, Polθ, and Werner programs that directly overlap with Repare's mechanism portfolio.

TypeDirect peer
Description

Precision oncology company developing targeted therapies based on novel genetic driver mutations in cancer, sharing Repare's biomarker-defined patient stratification approach.

TypeDirect peer
Description

Precision oncology company leveraging a proprietary chromatin biology platform for target discovery in cancer, comparable to Repare's platform-driven approach to identifying novel oncology targets.

TypeDirect peer
Description

Precision oncology company using motion-based computational chemistry to discover drugs against well-validated oncogenic targets — paralleling Repare's genomics-driven discovery model.

TypeBroad incumbent
Description

Established computational drug discovery platform serving pharma and running proprietary precision medicine programs, comparable to Repare's platform-led approach but at much broader scale across many therapeutic areas.

TypeBroad incumbent
Description

AI-driven drug discovery company with precision oncology and partnered programs, comparable to Repare's technology-enabled precision medicine discovery approach.

TypeBroad incumbent
Description

Clinical-stage oncology company with small-molecule and immuno-oncology programs, overlapping with Repare's clinical-stage cancer drug development focus.

TypeDirect peer
Description

Precision oncology biotech developing biomarker-driven therapies for defined patient populations, sharing Repare's strategic emphasis on genetically selected cancer indications.

TypeBroad incumbent
Description

Established precision oncology company (acquired by Bristol Myers Squibb) with targeted cancer therapies including KRAS inhibitors, sharing Repare's biomarker-led oncology strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Repare Therapeutics

Precision Oncology Drug Developmentreparerx.com

Repare Therapeutics was a Canadian clinical-stage precision oncology company that used its proprietary SNÅP synthetic lethality platform to develop DDR inhibitors targeting genetically defined cancer populations, monetizing its pipeline through licensing deals and acquisition rather than commercial product sales.

What Repare Therapeutics does

Repare Therapeutics was a Canadian clinical-stage precision oncology company founded in 2016 and headquartered in Montreal with research operations in Cambridge, UK. The company applied its proprietary SNÅP synthetic lethality platform to identify DNA damage response (DDR) vulnerabilities in cancer cells and develop targeted therapies for genomically defined patient populations. Its clinical pipeline included camonsertib (ATR inhibitor for ATM-deficient tumors, developed under a CRADA with the U.S. National Cancer Institute), RP-3467 (Polθ ATPase inhibitor evaluated in the POLAR Phase 1 trial), RP-1664 (PLK4 inhibitor in the LIONS Phase 1 trial for TRIM37-high solid tumors), and lunresertib (PKMYT1 inhibitor).

The company operated an asset-centric, partnership-driven business model with no commercial product revenue. It generated income by advancing clinical assets through early-stage development and then out-licensing or selling them to larger pharmaceutical partners — notably Gilead Sciences (RP-3467, up to $30 million), Debiopharm (lunresertib worldwide license), and DCx Biotherapeutics (discovery platforms plus retained talent). Following a 25% workforce reduction in September 2024 and a further 75% reduction in February 2025, Repare divested most of its remaining assets and was acquired by XenoTherapeutics, Inc. in January 2026 for approximately $78.2 million plus contingent value rights, resulting in delisting from Nasdaq.

Repare Therapeutics firmographics

Firmographics
Name
Repare Therapeutics
Legal name
Repare Therapeutics Inc.
Website
https://reparerx.com
Company type
Public
Founded year
2016
Operating status
Acquired
Headcount range
51–100 employees
Short description
Repare Therapeutics was a Canadian clinical-stage precision oncology company that used its proprietary SNÅP synthetic lethality platform to develop DDR inhibitors targeting genetically defined cancer populations, monetizing its pipeline through licensing deals and acquisition rather than commercial product sales.
Ownership category
akta.pro rank

Repare Therapeutics industry classification

Industry
Product category
Precision Oncology Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Precision oncology drugs
  • Synthetic lethality platform
  • DNA damage response inhibitors
  • Targeted cancer therapy
  • Clinical-stage biotechnology

Where Repare Therapeutics is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Repare Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Asset Licensing and Acquisition: Repare generated revenue through licensing agreements and asset sales to pharmaceutical partners. The company sold RP-3467 to Gilead Sciences for up to $30 million ($25M upfront + $5M milestone), licensed lunresertib to Debiopharm, and out-licensed discovery platforms to DCx Biotherapeutics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Repare Therapeutics product offering

Product offering

Core offering

Repare Therapeutics developed clinical-stage precision oncology drug candidates using its proprietary SNIPx synthetic lethality platform, which identifies synthetic lethal gene pairs to target DNA damage response vulnerabilities in genetically defined cancer patient populations. The company's pipeline included camonsertib (ATR inhibitor for ATM-deficient tumors), RP-3467 (Polθ ATPase inhibitor), RP-1664 (PLK4 inhibitor for TRIM37-high solid tumors), and lunresertib (PKMYT1 inhibitor). Value was realized through out-licensing clinical assets and discovery platforms to large pharmaceutical partners rather than direct commercialization.

Product overview

Repare Therapeutics was a clinical-stage precision oncology company developing targeted cancer therapies using its proprietary SNÅP synthetic lethality platform. The company's pipeline included multiple clinical-stage drug candidates: camonsertib (ATR inhibitor for ATM-deficient tumors), RP-1664 (PLK4 inhibitor in Phase 1 LIONS trial), and lunresertib (PKMYT1 inhibitor licensed to Debiopharm). Prior to its acquisition by XenoTherapeutics in January 2026, the company sold RP-3467 (Polθ ATPase inhibitor) to Gilead Sciences for up to $30 million and out-licensed its discovery platforms to DCx Biotherapeutics. The company's approach focused on developing therapies that exploit genomic instability in cancer cells while sparing normal cells.

Differentiator

Problem solved

Functional benefit

Products and services

  • Camonsertib (RP-3500) An ATR inhibitor designed for the treatment of ATM-deficient tumors through a synthetic lethality mechanism, inhibiting ATR kinase in tumors that lack ATM function. Developed for genetically defined patient populations with DNA repair deficiencies.
  • RP-3467 A polymerase theta (Polθ) ATPase inhibitor evaluated in the POLAR Phase 1 clinical trial for safety and preliminary activity alone or in combination with olaparib in patients with various advanced cancers. Acquired by Gilead Sciences in December 2025 for up to $30 million.
  • RP-1664 A PLK4 (Polo-like kinase 4) inhibitor evaluated in the Phase 1 LIONS clinical trial for solid tumors with TRIM37-high expression, representing a synthetic lethality approach to tumors with specific genomic alterations.
  • Lunresertib (RP-6306) A PKMYT1 inhibitor previously part of Repare's clinical pipeline for gynecologic cancers in combination with camonsertib. Exclusively licensed worldwide to Debiopharm in July 2025.
  • SNIPx Synthetic Lethality Discovery Platform Repare's proprietary drug discovery platform for identifying synthetic lethality targets in DNA damage response pathways, enabling the development of precision cancer therapies for genetically defined patient populations. Sold as a standalone offering through out-licensing to DCx Biotherapeutics.

Quantifiable outcome

  • 37.5% response rate in Phase 1 MYTHIC trial for lunresertib/camonsertib combination in advanced ovarian cancer
  • +1 more outcomes

Companies that use Repare Therapeutics

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Repare Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Repare Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • XenoTherapeuticscoreStrategic or Co-development Partner · 28 January 2026XenoTherapeutics, Inc., a Massachusetts-based 501(c)(3) nonprofit biotechnology research foundation focused on xenotransplantation, completed acquisition of Repare Therapeutics through a statutory plan of arrangement. Shareholders received cash payments and contingent value rights, resulting in delisting from Nasdaq and cessation of reporting obligations. Deal valued at approximately $78.2 million plus CVRs.
  • Gilead SciencescoreOEM/ Whitelabel/ Licensing Partner · 24 December 2025Gilead Sciences entered into a definitive asset purchase agreement to acquire Repare's Polθ ATPase inhibitor RP-3467 for up to $30 million, including $25 million upfront payment and $5 million upon technology transfer completion. The deal marked Repare's third and most significant portfolio transaction in 2025, with the upfront payment increasing shareholder payout in the pending XenoTherapeutics acquisition.
  • DebiopharmcoreOEM/ Whitelabel/ Licensing Partner · 1 August 2025Repare Therapeutics entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, continuing the companies' prior collaboration. This partnership followed Repare's portfolio reprioritization and cost reduction initiatives, allowing the company to focus on core clinical assets while enabling lunresertib's continued development.
  • DCx BiotherapeuticsminorOEM/ Whitelabel/ Licensing Partner · 4 May 2025Repare Therapeutics announced out-licensing of its discovery platforms to DCx Biotherapeutics, a newly launched company. The transaction included retention of talent and infrastructure from Repare to accelerate development of multi-modal antibody drug conjugates.
  • National Cancer Institute (NCI)coreStrategic or Co-development Partner · 15 November 2024Repare Therapeutics announced a CRADA (Cooperative Research and Development Agreement) with the US National Cancer Institute to advance development of camonsertib, an ATR inhibitor for ATM-deficient tumors. The partnership supports ongoing clinical development and provides access to NCI research capabilities and patient populations.

Scale indicators7 records

Recent moves7 records

Expansion highlights3 records

Repare Therapeutics competitors and assessment

Company assessment

Direct peers

  • Tango Therapeutics: Direct synthetic lethality competitor with a precision oncology pipeline targeting DNA damage response and other genetically defined vulnerabilities, using functional genomics screens comparable to Repare's SNIP platform.
  • Ideaya Biosciences: Precision oncology biotech developing synthetic lethality and DNA damage response (DDR) therapies, including MAT2A, Polθ, and Werner programs that directly overlap with Repare's mechanism portfolio.
  • Black Diamond Therapeutics: Precision oncology company developing targeted therapies based on novel genetic driver mutations in cancer, sharing Repare's biomarker-defined patient stratification approach.
  • Foghorn Therapeutics: Precision oncology company leveraging a proprietary chromatin biology platform for target discovery in cancer, comparable to Repare's platform-driven approach to identifying novel oncology targets.
  • Relay Therapeutics: Precision oncology company using motion-based computational chemistry to discover drugs against well-validated oncogenic targets — paralleling Repare's genomics-driven discovery model.
  • Elevation Oncology: Precision oncology biotech developing biomarker-driven therapies for defined patient populations, sharing Repare's strategic emphasis on genetically selected cancer indications.

Broad incumbents

  • Schrödinger: Established computational drug discovery platform serving pharma and running proprietary precision medicine programs, comparable to Repare's platform-led approach but at much broader scale across many therapeutic areas.
  • Exscientia: AI-driven drug discovery company with precision oncology and partnered programs, comparable to Repare's technology-enabled precision medicine discovery approach.
  • Arcus Biosciences: Clinical-stage oncology company with small-molecule and immuno-oncology programs, overlapping with Repare's clinical-stage cancer drug development focus.
  • Mirati Therapeutics: Established precision oncology company (acquired by Bristol Myers Squibb) with targeted cancer therapies including KRAS inhibitors, sharing Repare's biomarker-led oncology strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Repare Therapeutics social profiles

Digital presence

Repare Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Repare Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Repare Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Repare Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Repare Therapeutics

What does Repare Therapeutics do?

Repare Therapeutics developed clinical-stage precision oncology drug candidates using its proprietary SNIPx synthetic lethality platform, which identifies synthetic lethal gene pairs to target DNA damage response vulnerabilities in genetically defined cancer patient populations. The company's pipeline included camonsertib (ATR inhibitor for ATM-deficient tumors), RP-3467 (Polθ ATPase inhibitor), RP-1664 (PLK4 inhibitor for TRIM37-high solid tumors), and lunresertib (PKMYT1 inhibitor). Value was realized through out-licensing clinical assets and discovery platforms to large pharmaceutical partners rather than direct commercialization.

Is Repare Therapeutics a public or private company?

Repare Therapeutics is a public company. It is classified as nonprofit foundation owned and is currently acquired.

When was Repare Therapeutics founded?

Repare Therapeutics was founded in 2016. It employs 51 to 100 people.

Where is Repare Therapeutics based?

Repare Therapeutics is headquartered in Montreal, Canada, in the North America region.

How does Repare Therapeutics make money?

One revenue line is on record: asset Licensing and Acquisition.

Who are Repare Therapeutics's main competitors?

Direct peers on record are Tango Therapeutics, Ideaya Biosciences, Black Diamond Therapeutics, Foghorn Therapeutics, Relay Therapeutics and Elevation Oncology. Broad incumbents are Schrödinger, Exscientia, Arcus Biosciences and Mirati Therapeutics.

Does Repare Therapeutics have an API?

No public API is recorded for Repare Therapeutics.

What industry is Repare Therapeutics in?

Repare Therapeutics's product category is Precision Oncology Drug Development. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNext-Generation DNA Repair Inhibitors Could Capture Billions in Emerging MarketOnco-Innovations is developing ONC010, a nanoparticle-encapsulated PNKP inhibitor, with preclinical data showing doubled median survival in mice with colorectal cancer. The company plans a first-in-human phase 1 trial later this year, targeting a DNA repair pathway with no approved competitors.GlobeNewswireNext-Generation DNA Repair Therapies Open New Frontiers in OncologyOnco-Innovations is developing ONC010, a nanoparticle-encapsulated PNKP inhibitor targeting DNA repair, with exclusive global rights. Preclinical data showed median survival of 60 days in mice with PTEN-deficient colorectal cancer versus 23 days untreated. The company plans a first-in-human phase 1 trial in late 2026.Labiotech.euCan WEE1 inhibitors finally make replication stress druggable?WEE1 inhibitors are being revisited with improved selectivity and biomarker-defined patient populations. Early adavosertib showed activity but caused toxicity, while newer compounds like APR-1051 and azenosertib aim to reduce off-target effects. Trials are targeting replication-stress tumors, such as those with CCNE1 amplification.AD HOC NEWSRepare Therapeutics stock (US76094Q1022): Pipeline update frames the biotech's next catalystRepare Therapeutics, a Canadian biotech developing precision medicines for cancer, is focused on pipeline progress and financial activities as its next catalyst. The company's stock is heavily influenced by clinical data, financing steps, and strategic partnerships, especially in the US market.AD HOC NEWSRepare Therapeutics stock (US76094Q1022): Merck buyout and merger terms in focusRepare Therapeutics has agreed to be acquired by Merck in a cash-and-contingent value rights transaction that will take the precision oncology company private and delist its shares from Nasdaq. Under the deal terms, shareholders will receive a fixed cash payment at closing plus non-tradeable contingent value rights tied to developmental and regulatory milestones for specified pipeline assets, pending regulatory and shareholder approvals. The acquisition gives Merck access to Repare's synthetic lethality platform and clinical pipeline, while providing Repare shareholders with immediate liquidity and potential additional payments if development milestones are achieved.AD HOC NEWSRepare Therapeutics stock (US76094Q1022): Is its synthetic lethality focus strong enough to unlock bThis article provides an investment analysis of Repare Therapeutics, a clinical-stage biotech company utilizing its proprietary SNÅP synthetic lethality platform to develop precision cancer therapies targeting genetically defined patient populations. The piece examines the company's lead candidate camonsertib (an ATR inhibitor for ATM-deficient tumors), its broader pipeline including RP-6306, and positions it within the competitive synthetic lethality landscape alongside players like Ideaya Biosciences in a projected $50 billion-plus oncology market. The author advises investors to monitor upcoming clinical data readouts expected around 2026, potential partnership announcements with larger pharma, and cash runway updates as key catalysts, while cautioning on execution risks, clinical trial failures, and dilution concerns inherent to development-stage biotech investing.Simply Wall StGilead’s Growing Oncology Role Reshapes The Investment Case For GILDGilead Sciences has entered a licensing deal with Repare Therapeutics to expand its oncology pipeline, alongside Phase 3 data published in The New England Journal of Medicine for Trodelvy combined with Merck's Keytruda in first-line metastatic triple negative breast cancer. These developments position oncology as an increasingly central pillar of Gilead's long-term strategy alongside its established virology and HIV portfolio. Analysts note the stock trades approximately 49% below fair value estimates and has shown 17.5% positive momentum over the past 30 days.citybizRepare Shareholders Approve Acquisition by XenoTherapeuticsRepare Therapeutics Inc. shareholders have approved the acquisition of the company by XenoTherapeutics, Inc. and its subsidiary Xeno Acquisition Corp. through a statutory plan of arrangement, with 99.76% of votes cast in favor at a special meeting. The arrangement requires approval from the Superior Court of Québec, with a court hearing expected on January 23, 2026, and closing anticipated on or about January 28, 2026. XenoTherapeutics is a Massachusetts-based non-profit biotechnology research foundation focused on xenotransplantation.Stock TitanRepare shareholders approve sale to XenoTherapeuticsRepare Therapeutics Inc. shareholders voted overwhelmingly to approve the acquisition of the company by XenoTherapeutics, Inc. and Xeno Acquisition Corp. via a statutory plan of arrangement, with 99.76% of votes cast in favor at a special meeting on January 16, 2026. The transaction, valued at approximately 99.76% shareholder support, remains subject to Superior Court of Québec approval expected on January 23, 2026, with closing anticipated on or about January 28, 2026. XenoTherapeutics, a Massachusetts-based 501(c)(3) nonprofit focused on xenotransplantation research, is acquiring the clinical-stage precision oncology company, which has a pipeline including Phase 1 Polθ ATPase inhibitor and PLK4 inhibitor programs.FierceBiotechGilead garners lipid package for cancer asset in $300M research pactGilead Sciences has entered a research partnership with OncoNano Medicine valued at up to $300 million to access tumor-targeting lipid particles for its cancer drug candidates. The agreement includes an upfront payment, potential milestone payments, and royalties, allowing Gilead to utilize OncoNano's ON-BOARD capsule technology for localized drug delivery. This deal marks Gilead's second oncology-focused agreement in early January, following a separate acquisition of rights from Repare Therapeutics.